Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Quoted Innovation Diabetic Care

QUOTED. 14 December. Kevin Sayer.

  • News

Executive Summary

Dexcom’s management outlines its three-pronged growth strategy to reach $4-$4.5bn in revenues by 2025 during its recent investor day meeting. See what Dexcom’s CEO Kevin Sayer about it here.

“We really believe there will come a day in the US when people won’t be on finger sticks any more. This technology will be everywhere in the marketplace.” – Kevin Sayer, CEO, Dexcom

Click here for a free trial of Medtech Insight

Table

View full table

Related Content

Medtech Insight

Topics

Tags:
Quoted Innovation Diabetic Care
Latest Headlines

Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease

Small Sterilization Companies Poised To Meet EtO Emissions Goals On Time

At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use

UK MHRA Updates Assistive Tech And Borderline Regulations

See All
UsernamePublicRestriction

Register

MT143206

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By